Cavalier Investments’s Medifast MED Stock Holding History

Cavalier Investments’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-14,900	Closed	-$1.9M	–	133
2019 Q1	$1.9M	Hold	14,900	–	–	0.78%	37
2018 Q4	$1.86M	Hold	14,900	–	–	0.6%	27
2018 Q3	$3.3M	Hold	14,900	–	–	0.96%	24
2018 Q2	$2.39M	Buy	+14,900	New	+$1.9M	0.8%	27

Other funds holding MED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

HCM

Hoplite Capital Management New York $15.1M AUM 27.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAMU

Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Cavalier Investments's MED Position: Q2 2019 in Review

Cavalier Investments sold out of Medifast (MED) in Q2 2019, closing a stake of 14,900 shares — an estimated $1.9M sold.

Cavalier Investments first reported a position in MED in Q2 2018 and held it in 4 quarters. The position peaked at $3.3M in Q3 2018. 251 funds tracked by Wall St. Rank hold MED as of Q2 2019.

Cavalier Investments reported no remaining Medifast position as of Q2 2019 after selling out during the quarter.
Cavalier Investments sold 14,900 Medifast shares in Q2 2019, an estimated $1.9M.
Cavalier Investments first reported a position in Medifast in Q2 2018 and held it in 4 quarters.
Cavalier Investments's Medifast position peaked at $3.3M in Q3 2018.
251 funds tracked by Wall St. Rank held Medifast as of Q2 2019.

Based on Cavalier Investments's 13F filing for Q2 2019, filed 31 Jul 2019.